

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Pembrolizumab for previously treated solid tumours with high microsatellite instability or mismatch repair deficiency

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when no draft guidance was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No potential equality issues have been identified during the scoping process.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No.

- | |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? |
|--|

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of pembrolizumab for previously treated solid tumours with high microsatellite instability or mismatch repair deficiency

Issue date: August 2023

If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes. See section 3.18.

Approved by Associate Director (name): Linda Landells

Date: 27 July 2023